ImmuCell Corporation — Form 10-Q Summary
Reporting period: Quarter and nine months ended September 30, 2015. ImmuCell develops and sells animal-health products for dairy and beef cattle. First Defense, its calf-scours prevention product line, is the primary sales and profit driver; Mast Out, a mastitis treatment, remains under development.
Financial performance
| Metric | Q3 2015 | Q3 2014 | Nine months 2015 | Nine months 2014 |
|---|---|---|---|---|
| Product sales | $2.472 million | $1.770 million | $7.534 million | $5.392 million |
| Gross margin | $1.612 million; 65% | $1.078 million; 61% | $4.593 million; 61% | $3.106 million; 58% |
| Operating income (loss) | $627,000 | $41,000 | $1.661 million | ($405,000) |
| Net income (loss) | $351,000 | $10,000 | $924,000 | ($298,000) |
| Diluted earnings (loss) per share | $0.11 | $0.00 | $0.29 | ($0.10) |
- Cash flow: Nine-month operating cash flow was $2.070 million, versus $50,000 a year earlier. Capital expenditures were $1.772 million, versus $520,000. Cash and cash equivalents increased $1.619 million to $2.469 million.
- Liquidity: Cash, cash equivalents and investments totaled $6.676 million at September 30, up $2.841 million from year-end 2014. Net working capital was approximately $7.507 million.
- Debt: Bank debt totaled approximately $3.260 million, including a new $2.5 million mortgage received in Q3. Debt is secured by substantially all assets; the company reported compliance with applicable covenants and had an unused $500,000 line of credit.
- Balance sheet: Total assets were $14.223 million and stockholders’ equity was $10.298 million. Property, plant and equipment, net, was $4.956 million.
Material changes versus the prior comparable period
- Sales rose 40% in both Q3 and the first nine months. Growth was principally driven by First Defense and related products, which represented 88% of Q3 sales and 92% of nine-month sales.
- Gross margin percentage increased 4 percentage points in Q3 and 3 points year to date, reflecting higher sales and improved margins.
- Nine-month operating results moved from a loss to profit. Product development expense fell 47% to $904,000, largely following the prior-year investment in small-scale Nisin production; sales and marketing expense increased 18% to $1.087 million.
- Cash and investments increased, while total bank debt rose following the new mortgage financing. The company invested $1.772 million in property and equipment during the nine months.
Outlook, commentary and risks
- Management expects First Defense sales growth and recent profitability trends to continue, subject to production constraints. It targets a full-year gross margin above 50%; no specific revenue or earnings forecast is provided.
- First Defense demand exceeded capacity, leaving a reported $1.554 million order backlog at September 30. Liquid-processing capacity was increased by approximately 50% in Q4 2015; a further freeze-drying capacity expansion of approximately 100% was expected by the end of Q1 2016. Management warned that delays could risk customer losses.
- Management said existing resources should meet working-capital and operating needs for at least 12 months, but are insufficient for the contemplated commercial-scale Mast Out production facility. Estimated equipment costs are $10–15 million. The company was pursuing debt and/or equity financing and disclosed an effective Form S-3 registration statement for potential equity issuance of up to $10 million, subject to limits; issuance could dilute existing shareholders.
- Mast Out requires FDA approval. The Human Food Safety section was expected to be completed in 2016; management’s disclosed overall approval timeline was late 2018 or 2019, dependent on facility financing, construction, manufacturing submissions and FDA review. A zero milk-discard claim may offer differentiation, but potential interference with some cultured dairy production remains a risk.
- The company reported USDA concurrence in Q3 for rotavirus disease claims for a First Defense product extension and said licensure and launch could be possible in 2016, subject to remaining laboratory and manufacturing requirements.
- Key risks include reliance on First Defense and a small number of distributors, capacity-related backlog, competition, variable dairy and beef economics, regulatory and development uncertainty, dependence on key suppliers and personnel, and potential dilution from financing. Two distributors accounted for 63% of nine-month sales; the largest accounted for 41%.
- Subsequent events included an October 2015 syringe-supply agreement extension through 2020, the effective equity shelf registration, and the board’s decision to exercise an option to acquire nearby land for a potential Mast Out facility. The land purchase price was $238,000 before credit for the option payment.
- Management concluded disclosure controls were effective; no material change in internal control over financial reporting was reported. No legal proceedings or market-risk disclosures were reported.
Most important facts for investors to verify
- Whether production expansions reduce the $1.554 million backlog without impairing customer retention or margins.
- Actual timing, cost, financing and potential dilution associated with the commercial-scale Mast Out facility.
- Progress toward Mast Out FDA approval, including completion of the Human Food Safety and Chemistry, Manufacturing and Controls sections.
- Whether First Defense growth and gross margins are sustainable given customer concentration, competition, and dairy and beef market conditions.
- How much equity, if any, is issued under the effective Form S-3 and how proceeds are used.
- Realizability of deferred tax assets: the company reported $613,000 in deferred tax assets, no valuation allowance, and noted that realization depends on future taxable income.